Prediction of Mortality With the Use of Noninvasive Ventilation for Acute Respiratory Failure.


Journal

Respiratory care
ISSN: 1943-3654
Titre abrégé: Respir Care
Pays: United States
ID NLM: 7510357

Informations de publication

Date de publication:
Dec 2020
Historique:
pubmed: 28 8 2020
medline: 23 2 2021
entrez: 27 8 2020
Statut: ppublish

Résumé

In actuality, it is difficult to obtain an early prognostic stratification for patients with acute respiratory failure treated with noninvasive ventilation (NIV). We tested whether an early evaluation through a predictive scoring system could identify subjects at risk of in-hospital mortality or NIV failure. This was a retrospective study, which included all the subjects with acute respiratory failure who required NIV admitted to an emergency department-high-dependence observation unit between January 2014 and December 2017. The HACOR (heart rate, acidosis [by using pH], consciousness [by using the Glasgow coma scale], oxygenation [by using [Formula: see text]/[Formula: see text]], respiratory rate) score was calculated before the NIV initiation (T0) and after 1 h (T1) and 24 h (T24) of treatment. The primary outcomes were in-hospital mortality and NIV failure, defined as the need for invasive ventilation. The study population included 644 subjects, 463 with hypercapnic respiratory failure and an overall in-hospital mortality of 23%. Thirty-six percent of all the subjects had NIV as the "ceiling" treatment. At all the evaluations, nonsurvivors had a higher mean ± SD HACOR score than did the survivors (T0, 8.2 ± 4.9 vs 6.1 ± 4.0; T1, 6.6 ± 4.8 vs 3.8 ± 3.4; T24, 5.3 ± 4.5 vs 2.0 ± 2.3 [all Among the subjects treated with NIV for acute respiratory failure, the HACOR score seemed to be a useful tool to identify those at risk of in-hospital mortality.

Sections du résumé

BACKGROUND BACKGROUND
In actuality, it is difficult to obtain an early prognostic stratification for patients with acute respiratory failure treated with noninvasive ventilation (NIV). We tested whether an early evaluation through a predictive scoring system could identify subjects at risk of in-hospital mortality or NIV failure.
METHODS METHODS
This was a retrospective study, which included all the subjects with acute respiratory failure who required NIV admitted to an emergency department-high-dependence observation unit between January 2014 and December 2017. The HACOR (heart rate, acidosis [by using pH], consciousness [by using the Glasgow coma scale], oxygenation [by using [Formula: see text]/[Formula: see text]], respiratory rate) score was calculated before the NIV initiation (T0) and after 1 h (T1) and 24 h (T24) of treatment. The primary outcomes were in-hospital mortality and NIV failure, defined as the need for invasive ventilation.
RESULTS RESULTS
The study population included 644 subjects, 463 with hypercapnic respiratory failure and an overall in-hospital mortality of 23%. Thirty-six percent of all the subjects had NIV as the "ceiling" treatment. At all the evaluations, nonsurvivors had a higher mean ± SD HACOR score than did the survivors (T0, 8.2 ± 4.9 vs 6.1 ± 4.0; T1, 6.6 ± 4.8 vs 3.8 ± 3.4; T24, 5.3 ± 4.5 vs 2.0 ± 2.3 [all
CONCLUSIONS CONCLUSIONS
Among the subjects treated with NIV for acute respiratory failure, the HACOR score seemed to be a useful tool to identify those at risk of in-hospital mortality.

Identifiants

pubmed: 32843508
pii: respcare.07464
doi: 10.4187/respcare.07464
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1847-1856

Informations de copyright

Copyright © 2020 by Daedalus Enterprises.

Déclaration de conflit d'intérêts

The authors have no conflict of interest to declare.

Auteurs

Francesca Innocenti (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy. innocenti.fra66@gmail.com.

Laura Giordano (L)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Simona Gualtieri (S)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Arianna Gandini (A)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Lucia Taurino (L)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Monica Nesa (M)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Chiara Gigli (C)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Alessandro Becucci (A)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Alessandro Coppa (A)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Irene Tassinari (I)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Maurizio Zanobetti (M)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Francesca Caldi (F)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Riccardo Pini (R)

High-Dependency Unit, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH